Creating a more strategic small molecule biophysical hit characterization workflow

IF 2.7 4区 生物学 Q2 BIOCHEMICAL RESEARCH METHODS SLAS Discovery Pub Date : 2024-05-07 DOI:10.1016/j.slasd.2024.100159
Christopher Fotsch , Debaleena Basu , Ryan Case , Qing Chen , Pratibha C. Koneru , Mei-Chu Lo , Rachel Ngo , Pooja Sharma , Amit Vaish , Xiang Yi , Stephan G. Zech , Peter Hodder
{"title":"Creating a more strategic small molecule biophysical hit characterization workflow","authors":"Christopher Fotsch ,&nbsp;Debaleena Basu ,&nbsp;Ryan Case ,&nbsp;Qing Chen ,&nbsp;Pratibha C. Koneru ,&nbsp;Mei-Chu Lo ,&nbsp;Rachel Ngo ,&nbsp;Pooja Sharma ,&nbsp;Amit Vaish ,&nbsp;Xiang Yi ,&nbsp;Stephan G. Zech ,&nbsp;Peter Hodder","doi":"10.1016/j.slasd.2024.100159","DOIUrl":null,"url":null,"abstract":"<div><p>To confirm target engagement of hits from our high-throughput screening efforts, we ran biophysical assays on several hundreds of hits from 15 different high-throughput screening campaigns. Analyzing the biophysical assay results from these screening campaigns led us to conclude that we could be more strategic in our biophysical analysis of hits by first confirming activity in a thermal shift assay (TSA) and then confirming activity in either a surface plasmon resonance (SPR) assay or a temperature-related intensity change (TRIC) assay. To understand how this new workflow shapes the quality of the final hits, we compared TSA/SPR or TSA/TRIC confirmed and unconfirmed hits to one another using four measures of compound quality: quantitative estimate of drug-likeness (QED), Pan-Assay Interference Compounds (PAINS), promiscuity, and aqueous solubility. In general, we found that the biophysically confirmed hits performed better in the compound quality metrics than the unconfirmed hits, demonstrating that our workflow not only confirmed target engagement of the hits but also enriched for higher quality hits.</p></div>","PeriodicalId":21764,"journal":{"name":"SLAS Discovery","volume":"29 4","pages":"Article 100159"},"PeriodicalIF":2.7000,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2472555224000212/pdfft?md5=389ec9b1863fb13b54ef5a3823355f2d&pid=1-s2.0-S2472555224000212-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SLAS Discovery","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2472555224000212","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

Abstract

To confirm target engagement of hits from our high-throughput screening efforts, we ran biophysical assays on several hundreds of hits from 15 different high-throughput screening campaigns. Analyzing the biophysical assay results from these screening campaigns led us to conclude that we could be more strategic in our biophysical analysis of hits by first confirming activity in a thermal shift assay (TSA) and then confirming activity in either a surface plasmon resonance (SPR) assay or a temperature-related intensity change (TRIC) assay. To understand how this new workflow shapes the quality of the final hits, we compared TSA/SPR or TSA/TRIC confirmed and unconfirmed hits to one another using four measures of compound quality: quantitative estimate of drug-likeness (QED), Pan-Assay Interference Compounds (PAINS), promiscuity, and aqueous solubility. In general, we found that the biophysically confirmed hits performed better in the compound quality metrics than the unconfirmed hits, demonstrating that our workflow not only confirmed target engagement of the hits but also enriched for higher quality hits.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
创建更具战略性的小分子生物物理命中表征工作流程。
为了确认高通量筛选工作中筛选出的目标参与,我们对 15 次不同的高通量筛选活动中筛选出的数百个目标进行了生物物理测定。通过分析这些筛选活动的生物物理检测结果,我们得出结论:首先在热转移检测(TSA)中确认活性,然后在表面等离子体共振(SPR)检测或温度相关强度变化(TRIC)检测中确认活性,这样就能更有策略地对筛选结果进行生物物理分析。为了了解这一新的工作流程如何影响最终结果的质量,我们使用四种化合物质量衡量标准对 TSA/SPR 或 TSA/TRIC 确认结果和未确认结果进行了比较:药物相似性定量估计 (QED)、泛分析干扰化合物 (PAINS)、杂合性和水溶性。总的来说,我们发现生物物理确认的命中化合物在化合物质量指标中的表现优于未确认的命中化合物,这表明我们的工作流程不仅确认了命中化合物的靶点参与,而且还富集了更高质量的命中化合物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
SLAS Discovery
SLAS Discovery Chemistry-Analytical Chemistry
CiteScore
7.00
自引率
3.20%
发文量
58
审稿时长
39 days
期刊介绍: Advancing Life Sciences R&D: SLAS Discovery reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease. SLAS Discovery is a peer-reviewed journal that publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success. SLAS Discovery emphasizes scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics). Review articles on target biology, new paradigms in drug discovery and advances in drug discovery technologies. SLAS Discovery is of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology. SLAS Discovery is a member of the Committee on Publication Ethics (COPE) and was published previously (1996-2016) as the Journal of Biomolecular Screening (JBS).
期刊最新文献
A secretome screen in primary human lung fibroblasts identifies FGF9 as a novel regulator of cellular senescence Corelet™ platform: Precision high throughput screening for targeted drug discovery of biomolecular condensates Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids A novel high-throughput screening platform to identify inhibitors of DNAJB1-PRKACA-driven transcriptional activity in fibrolamellar carcinoma Comparative evaluation of cell-based assay technologies for scoring drug-induced condensation of SARS-CoV-2 nucleocapsid protein
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1